- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Trend analysis of ANDA after the implementation of the drug patent linkage system in China
- ZHONGGUO YAOFANG Vol. 35, Issue 21, Pages: 2577-2581(2024)
- 作者机构：
南京中医药大学卫生经济管理学院，南京 210023
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.21.01
CLC： R95Published：15 November 2024，
Received：03 June 2024，
Revised：06 October 2024，
- 稿件说明：
移动端阅览
姚雪芳,张妍.药品专利链接制度实施后我国仿制药申请态势分析 Δ[J].中国药房,2024,35(21):2577-2581.
YAO Xuefang,ZHANG Yan.Trend analysis of ANDA after the implementation of the drug patent linkage system in China[J].ZHONGGUO YAOFANG,2024,35(21):2577-2581.
姚雪芳,张妍.药品专利链接制度实施后我国仿制药申请态势分析 Δ[J].中国药房,2024,35(21):2577-2581. DOI： 10.6039/j.issn.1001-0408.2024.21.01.
YAO Xuefang,ZHANG Yan.Trend analysis of ANDA after the implementation of the drug patent linkage system in China[J].ZHONGGUO YAOFANG,2024,35(21):2577-2581. DOI： 10.6039/j.issn.1001-0408.2024.21.01.
摘要
目的
2
为完善药品专利链接制度提供参考。
方法
2
通过中国上市药品专利信息登记平台的“专利声明”和“专利信息公示”模块获取药品名称、药品类型、仿制药申请（ANDA）受理号、注册分类、申请人名称等数据，数据收集时间为2021年7月4日至2023年9月30日。对最终纳入统计的ANDA品种的专利声明年度分布、不同注册分类占比、4类声明细化情况、3类声明对应专利剩余有效期以及同品种厂家数进行分析。
结果
2
在统计的ANDA品种中，以1类声明为主（占比为86.53%），2、3、4类声明占比均在4%～5%之间。在3项注册分类上，注册分类3中1类声明占比高达98.55%；注册分类4中1类声明占比为79.65%，而2、3、4类声明占比均在7%左右。在4类声明的细化类别上，4.2类声明占比（79.23%）较大，并呈小幅上升趋势，相对而言4.1类声明挑战较少。3类声明对应专利剩余有效期过长，中位数为18个月。同品种申报厂家数＜5家的占比为36.44%，≥20家的占比为14.75%。
结论
2
我国ANDA在实践中已有序衔接药品专利链接制度；建议在专利声明登记与异议机制、3类声明类ANDA的批准生效日期、4.1类声明的激励措施等方面予以优化，从而进一步规范ANDA秩序，引导仿制药高质量发展。
Abstract
OBJECTIVE
2
To provide a reference for improving the drug patent linkage system.
METHODS
2
Data on drug names， drug types， abbreviated new drug application （ANDA） acceptance numbers， registration classifications， and applicant names were obtained from the patent certifications and patent information disclosure modules of China’s patent information registration platform for marketed drugs. The data collection period was from July 4， 2021， to September 30， 2023. The analysis focused on the annual distribution of patent certifications for the ANDA varieties included in the statistics， the proportion of different registration classifications， the details of the type Ⅳ certifications， the remaining validity periods of the corresponding patents for the type Ⅲ certifications， and the number of manufacturers for the same variety.
RESULTS
2
Among the ANDA varieties analyzed， type Ⅰ certifications predominated （accounting for 86.53%）， while types Ⅱ， Ⅲ and Ⅳ certifications each accounted for approximately 4% to 5%. In the three registration classifications， type Ⅰ certifications in registration classification 3 accounted for as high as 98.55%， and in registration classification 4， type Ⅰ certifications accounted for 79.65%， while types Ⅱ， Ⅲ and Ⅳ certifications each accounted for around 7%. In terms of the detailed type of the Ⅳ certifications， type Ⅳ of article 2 certifications had a large proportion （79.23%） and showed a slight upward trend， whereas the challenges of type Ⅳ of article 1 certifications were few. The remaining validity period of the patents corresponding to type Ⅲ certifications was excessively long， with a median of 18 months. The proportion of the same variety with fewer than 5 manufacturers was 36.44%， while those with more than or equal to 20 manufacturers accounted for 14.75%.
CONCLUSIONS
2
The ANDA system in China has been orderly integrated with the drug patent linkage system in practice. It is recommended to optimize aspects such as patent certifications registration and objection mechanisms， the effective approval dates for ANDA with type Ⅲ certifications， and incentive measures for type Ⅳ of article 1 certifications， thereby further standardizing the ANDA process and guiding the high-quality development of generic drugs.
关键词
药品专利链接制度仿制药申请专利声明态势分析
Keywords
ANDApatent certificationstrend analysis
references
国家药品监督管理局，国家知识产权局.国家药监局 国家知识产权局关于发布《药品专利纠纷早期解决机制实施办法（试行）》的公告：2021年第89号[EB/OL]. [2024-01-29]. https：//www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210703223942131.htmlhttps://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210703223942131.html.
National Medical Products Administration，China National Intellectual Property Administration. Announcement of the National Medical Products Administration and the China National Intellectual Property Administration on issuing the implementation measures for The Mechanism for Early Resolution of Pharmaceutical Patent Disputes （Trial）：No. 89 of 2021[EB/OL].[2024-01-29].https：//www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210703223942131.htmlhttps://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210703223942131.html.
姚雪芳，张国成，丁锦希. 我国推行药品专利链接制度的可行性研究：基于利益相关方分析法[J]. 中国新药杂志，2016，25（24）：2814-2820.
YAO X F，ZHANG G C，DING J X. Feasibility study on the implementation of patent linkage system in China：based on analysis of stakeholders[J]. Chin J New Drugs，2016，25（24）：2814-2820.
冯振龙，周莹. 仿制药专利挑战行为拟制侵权的合理性证成及制度建构[J]. 中国科技论坛，2023（4）：142-150，157.
FENG Z L，ZHOU Y. Rationalization and institutional construction of artificial infringement of generic drug patent challenge[J]. Forum Sci Technol China，2023（4）：142-150，157.
陈烨，刘心玥，丁小米，等. 专利药品基本医疗保险目录准入路径研究[J]. 中国医药工业杂志，2023，54（11）：1663-1670.
CHEN Y，LIU X Y，DING X M，et al. Study on the access path for patented drugs to the basic national medical insu- rance catalogue[J]. Chin J Pharm，2023，54（11）：1663-1670.
唐运舒，叶徽，焦建玲，等. 药品集采、以量换价与药企创新：如何实现医药减负与药企创新发展的双赢?[J]. 中国软科学，2023（12）：123-133.
TANG Y S，YE H，JIAO J L，et al. Centralized drug procurement，volume-for-price，and pharmaceutical enterprise innovation：how to achieve a win-win for pharmaceutical burden reduction and innovative development of pharmaceutical enterprises?[J]. China Soft Sci，2023（12）：123-133.
国家药品监督管理局药品审评中心. 2021年度药品审评报告[EB/OL].[2024-07-22]. https：//www.cde.org.cn/main/news/viewInfoCommon/f92b7bdf775bbf4c4dc3a762-f343cdc8https://www.cde.org.cn/main/news/viewInfoCommon/f92b7bdf775bbf4c4dc3a762-f343cdc8.
National Medical Products Administration Drug Evaluation Center. Annual drug review report 2021[EB/OL].[2024-07-22]. https：//www.cde.org.cn/main/news/viewInfoCommon/f92b7bdf775bbf4c4dc3a762f343cdc8https://www.cde.org.cn/main/news/viewInfoCommon/f92b7bdf775bbf4c4dc3a762f343cdc8.
陈烨，刘心玥，丁锦希. 全生命周期下药品专利链接制度的实施问题与优化[J]. 中国医药工业杂志，2023，54（10）：1496-1503.
CHEN Y，LIU X Y，DING J X. Implementation issues and optimization of drug patent linkage system under the whole life cycle[J]. Chin J Pharm，2023，54（10）：1496-1503.
Administrative Committee of the Federal Register. U.S. code of federal regulations，21 CFR§314.105（d）[EB/OL].[2024-01-29]. https：//www.govregs.com/regulations/title21_ chapterI-i4_part314_subpartD_section314.105https://www.govregs.com/regulations/title21_chapterI-i4_part314_subpartD_section314.105.
国家组织药品联合采购办公室. 全国药品集中采购文件（GY-YD2023-1）公告：国联采字〔2023〕1号[EB/OL]. [2024-01-29]. https：//si12333.cn/policy/mryry.htmlhttps://si12333.cn/policy/mryry.html.
Office of Joint Procurement of Medicines by State Organizations.National centralized drug purchasing document （GY-YD2023-1）：GY-YD〔2023〕No.1[EB/OL].[2024-01-29]. https：//si12333.cn/policy/mryry.htmlhttps://si12333.cn/policy/mryry.html.
国家药品监督管理局药品审评中心.2013年度药品审评报告[EB/OL].[2024-01-29]. https：//www.cde.org.cn/main/news/viewInfoCommon/821e227c1c5a6b40d2e5b841d05-e8b69https://www.cde.org.cn/main/news/viewInfoCommon/821e227c1c5a6b40d2e5b841d05-e8b69.
National Medical Products Administration Drug Evaluation Center.Annual drug review report 2013[EB/OL].[2024-01-29]. https：//www.cde.org.cn/main/news/viewInfoCommon/821e227c1c5a6b40d2e5b841d05e8b69https://www.cde.org.cn/main/news/viewInfoCommon/821e227c1c5a6b40d2e5b841d05e8b69.
国家药品监督管理局药品审评中心.2014年度药品审评报告[EB/OL].[2024-01-29]. https：//www.cde.org.cn/main/news/viewInfoCommon/e0632749b6c4697922e4b1b06d3-bcabehttps://www.cde.org.cn/main/news/viewInfoCommon/e0632749b6c4697922e4b1b06d3-bcabe.
National Medical Products Administration Drug Evaluation Center. Annual drug review report 2014[EB/OL].[2024-01-29]. https：//www.cde.org.cn/main/news/viewInfoCommon/e0632749b6c4697922e4b1b06d3bcabehttps://www.cde.org.cn/main/news/viewInfoCommon/e0632749b6c4697922e4b1b06d3bcabe.
国家药品监督管理局药品审评中心.2015年度药品审评报告[EB/OL].[2024-01-29]. https：//www.cde.org.cn/main/news/viewInfoCommon/962da6d54695d4f2f91faef72d1b-6776https://www.cde.org.cn/main/news/viewInfoCommon/962da6d54695d4f2f91faef72d1b-6776.
National Medical Products Administration Drug Evaluation Center.Annual drug review report 2015[EB/OL].[2024-01-29]. https：//www.cde.org.cn/main/news/viewInfoCommon/962da6d54695d4f2f91faef72d1b6776https://www.cde.org.cn/main/news/viewInfoCommon/962da6d54695d4f2f91faef72d1b6776.
祝高峰，魏琦. 中国药品专利链接制度设计的内涵、现状及其应对[J]. 中国发明与专利，2023，20（9）：48-55.
ZHU G F，WEI Q. The connotation，current situation，and response of China’s drug patent linkage system design[J]. China Invent Pat，2023，20（9）：48-55.
曹嘉成，樊嘉训，王闻珠. 专利链接制度对我国仿制药申报的激励效果分析及对策建议[J]. 中国药房，2023，34（19）：2311-2315.
CAO J C，FAN J X，WANG W Z. Analysis of the incentive effect of the patent linkage system on the application of generic drugs in China and suggestions for countermeasures[J]. China Pharm，2023，34（19）：2311-2315.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.